Nexvet Biopharma plc Ordinary Shares
NVET
NVET was delisted on the 28th of July, 2017.
20 hedge funds and large institutions have $35.8M invested in Nexvet Biopharma plc Ordinary Shares in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 6 closing their positions.
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
59% more capital invested
Capital invested by funds: $22.6M → $35.8M (+$13.2M)
54% more funds holding
Funds holding: 13 → 20 (+7)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KAM
Kassirer Asset Management
Toronto,
Ontario, Canada
|
+$755K |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$660K |
| 3 |
GF
Gabelli Funds
Rye,
New York
|
+$553K |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$535K |
| 5 |
GCIA
Gabelli & Co Investment Advisers
Rye,
New York
|
+$447K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$3.41M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$602K |
| 3 |
LLC
Latimer Light Capital
New York
|
-$408K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$173K |
| 5 |
Citigroup
New York
|
-$21K |
NVET Hedge Fund Activity: Q2 2017 in Review
20 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Nexvet Biopharma plc Ordinary Shares (NVET) for Q2 2017, worth a combined $35.8M — up 59% from $22.6M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new NVET positions and 6 closed out — a net gain of 7 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Kassirer Asset Management, opening a new position worth an estimated $755K. The largest seller was Foresite Capital Management II, exiting entirely with an estimated $3.41M sold.
- 20 institutional investors held Nexvet Biopharma plc Ordinary Shares (NVET) as of Q2 2017, up from 13 in Q1 2017.
- Funds reported $35.8M of Nexvet Biopharma plc Ordinary Shares stock for Q2 2017, up 59% quarter-over-quarter.
- 13 funds opened new Nexvet Biopharma plc Ordinary Shares positions in Q2 2017 and 6 closed out, a net change of +7 holders.
- The largest Nexvet Biopharma plc Ordinary Shares buyer in Q2 2017 was Kassirer Asset Management, an estimated $755K added.
- The largest Nexvet Biopharma plc Ordinary Shares seller in Q2 2017 was Foresite Capital Management II, an estimated $3.41M sold.
Based on aggregated 13F filings for Q2 2017.